Evidence map›Paper›PMID 39761829›Full record

Trial reportChest2025

Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.

Peter J Leary, Samuel G Rayner, Kelley R H Branch, Laurie Hogl, Nancy M Liston, Lia M Barros, Jessi Prout, Stephanie Nolley, Jonathan Buber, David D Ralph and 1 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Chest, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03554291 (Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03554291 phase2completednot on this map

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

TypeinterventionalSponsorUniversity of WashingtonRan2019 to 2023Enrolled80ConditionsPulmonary Arterial Hypertension, Right Heart FailureArmsFamotidine 20 MG, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Peter J LearyDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA; Department of Epidemiology, University of Washington, Seattle, WA. Electronic address: learyp@uw.edu.
Samuel G RaynerDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Kelley R H BranchDivision of Cardiology, University of Washington, Seattle, WA.
Laurie HoglDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Nancy M ListonDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Lia M BarrosDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Jessi ProutDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Stephanie NolleyDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Jonathan BuberDivision of Cardiology, University of Washington, Seattle, WA.
David D RalphDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Jeffrey L ProbstfieldDivision of Cardiology, University of Washington, Seattle, WA.

Funding

NHLBI NIH HHS R33 HL142539NHLBI NIH HHS R61 HL142539
6 · The paper itself

Abstract

backgroundAdaptation of the right ventricle is a key determinant of outcomes in pulmonary arterial hypertension (PAH). Despite a compelling rationale to develop targeted therapies for the right ventricle in PAH, no such treatments exist. H RESEARCH QUESTION: Do H STUDY DESIGN AND

methodsWe conducted a 24-week, single-center, 1:1 randomized, double-masked, placebo-controlled trial of the H

resultsFrom May 2019 through July 2023, 80 participants were randomized with 79 receiving study drug. No significant difference in the primary outcome of 6MWD at 24 weeks was found, with an increase of 4.7 m seen in the placebo arm vs a decrease of 17.0 m in the famotidine arm (P = .24). Also no differences were found in secondary end points at 24 weeks. Study drug was well tolerated, and safety profiles were similar between arms. Adherence and study conduct were good overall. Participants with methamphetamine-associated PAH were similar in all aspects to the study participants more broadly.

interpretationThe results of this trial do not support the routine use of famotidine 20 mg daily as an adjunct therapy for the treatment of PAH. The findings of the Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension (REHAB-PH) trial argue against the practice of avoiding participants with methamphetamine-associated PAH in randomized clinical trials of novel therapies. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03554291; URL: www. CLINICALTRIALS: gov.

Indexed as

FamotidineHistamine H2 AntagonistsPulmonary Arterial HypertensionAdultAgedDouble-Blind MethodEchocardiographyFemaleHumansMaleMiddle AgedQuality of LifeTreatment OutcomeWalk TestFamotidineHistamine H2 Antagonistscor pulmonaleheart failurehistaminic signalingmethamphetaminepulmonary hypertensionright ventricular adaptation

Identifiers

PMID39761829
PMCPMC12264346

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.